

Jaguar Health, Inc.
(NASDAQ: JAGX)

Overview – December 2024



Forward-Looking Statements

This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding plans by Jaguar Health, Inc. (“Jaguar” or the “Company”) and Napo Therapeutics (formerly known as “Napo EU”) to develop and commercialize crofelemer in Europe for HIV-related diarrhea, short bowel syndrome, congenital diarrheal disorders, and other indications, expectations related to the timing of the commercial launch of products in any market, the expectation that Magdalena Biosciences will leverage Jaguar’s proprietary medicinal plant library and Filament Health’s proprietary drug development technology, the expectation that US\$1,000,000 will be invested in Magdalena Biosciences by One Small Planet, the expectation that Magdalena Biosciences may develop a potential plant-based alternative drug for adult ADHD or other indications that is both safe and efficacious, Jaguar’s plans to pursue additional business development deals, plans to expand the geography for commercialization of crofelemer, statements related to the powder formulation of crofelemer, related to NP-300, the timing of the initiation, completion, results, and publication of Phase 2 studies, Phase 3 studies, proof-of-concept studies, field studies, investigator-initiated trials, sponsored studies, and other studies, statements about possible eligibility for, and possible participation in, revenue generating early access programs, statements about the planned submission of Investigational New Drug (IND) applications to FDA, statements about plans to pursue a Priority Review Voucher (PRV), statements about the possible future market size/potential of indications, and expected milestones appearing on the list of “Upcoming Milestones”, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Please see the risk factors identified in our Annual Report on Form 10-K and our other filings with the SEC. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Readers are also advised that our projected sales do not take into account the royalties and other payments we will need to make to our licensors and strategic partners. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

What We Do: Develop New Ways and Novel Plant-based Medicines to Treat Gastrointestinal Disorders

From Tree to Bottle

Crofelemer was discovered through the science of ethnobotany



Canalevia®-CA1 is conditionally approved by the FDA for the treatment of chemotherapy-induced diarrhea in dogs



Mytesi (crofelemer 125mg delayed-release tablets) is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy

Jaguar/Napo Product Portfolio – Crofelemer Pipeline in a Product


PRODUCT	INDICATIONS EVALUATED	DEVELOPMENT STAGE					
		PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	APPROVED (US)	GEOGRAPHIC FOCUS OF CLINICAL STUDIES
Mytesi (crofelemer)	Noninfectious diarrhea in adults with HIV/AIDS antiretroviral therapy						US
Crofelemer	Cancer therapy-related diarrhea (CTD)					<i>Phase 3 OnTarget trial completed</i>	Global
Highly concentrated liquid formulation of crofelemer	Adult short bowel syndrome with intestinal failure (SBS-IF)						US, EU MENA
Highly concentrated liquid formulation of crofelemer	Pediatric microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD)						US, EU & MENA
Crofelemer	IBS - Diarrhea Predominant (IBS-D)					<i>Oct 2024: Poster at American College of Gastroenterology Annual Meeting</i>	US
Crofelemer	Chronic idiopathic diarrhea in non-HIV patients					<i>Oct 2024: Poster at American College of Gastroenterology Annual Meeting</i>	US
NP-300*	Symptomatic relief of diarrhea from cholera		<i>See footnotes below</i>			<i>US IND in effect with FDA</i>	US

*NP-300 and crofelemer have a similar physiological anti-secretory mechanism of action to reduce chloride ion secretion into the gut lumen and improve stool consistency. The Company has previously presented Phase 2 data on crofelemer for the treatment of devastating dehydration in cholera patients from the renowned International Centre for Diarrhoeal Disease Research (icDDR,b) in Bangladesh.

*Potential opportunity for Priority Review Voucher (PRV)

Robustness: Financially, Clinically, Commercially

- **Financial Robustness:** Net Q3 2024 revenue increased 14% versus net Q2 2024 revenue
- **Clinical Robustness/Near-Term Catalysts:**
 - Crofelemer in development for multiple possible follow-on indications:
 - Five rare/orphan disease indication clinical catalysts in Q4 2024/Q1 2025: SBS-IF and MVID
 - Phase 3 data with statistically significant improvement in prespecified subgroup of adult patients with breast cancer
 - Two investigator-initiated responder analysis trials of crofelemer show significant results in IBS-D; Data presented at October 2024 American College of Gastroenterology Annual Meeting
 - Proprietary anti-secretory antidiarrheal drug for cholera-related diarrhea (potential opportunity for FDA tropical disease priority review voucher) – IND approve
 - Jaguar JV Magdalena Biosciences opportunity to file IND for 3 psychoactive botanical drug candidates in 2025
- **Commercial Robustness:** October 2024 commercial launch of the FDA-approved oral mucositis prescription product Gelclair in U.S.



Oct 1, 2024: Jaguar Reports Statistically Significant Improvement in Breast Cancer Patients in OnTarget

- Crofelemer achieved **statistical significance** in **prespecified subgroup of adult patients with breast cancer** from OnTarget. **Results in breast cancer patients accepted for poster presentation at December 2024 San Antonio Breast Cancer Symposium (SABCS).**
 - Data presented at SABCS will serve as cornerstone of briefing package Napo plans to submit to FDA to request meeting to discuss possible pathways to make crofelemer available as efficiently as possible to breast cancer patients.
 - Full study report on breast cancer subgroup analysis expected to be submitted to peer-reviewed journal by study's primary investigators.
- Breast cancer patients accounted for majority of OnTarget participants.
- OnTarget breast cancer results are a **responder analysis**, as was the primary endpoint in phase 3 ADVENT trial that led to FDA approval of crofelemer for currently commercialized indication of HIV-related diarrhea.
- Additional analyses of OnTarget ongoing, and data from additional analyses is expected to also qualify for submission to peer-reviewed forums.



Increasing Market Value: Progression from Supportive Care to Impact on Outcome/Cost of Care to Treatment Modifying

Indication	# of Competitors	Market Size/Potential
HIV-related diarrhea	0	Jaguar estimates the U.S. market revenue potential for Mytesi® to be ~\$50 million in gross annual sales
Cancer therapy-related diarrhea (CTD)	0	Projected to be 2.0 million new cancer cases in US in 2024 ² >1 million cancer patients receive chemo or radiation in a US outpatient clinic annually ³ Comparable supportive care (CINV) global market projected to reach \$4.3 billion by 2031 ⁴
Short bowel syndrome (SBS) with intestinal failure / Microvillus inclusion disease (MVID), a congenital diarrheal disorder (CDD)	0	~10,000 to 20,000 people in US have SBS and approximately the same number in Europe. Orphan-drug designation supports potential accelerated approval. Estimated annual US revenue for Takeda's SBS drug Gattex: ~\$555 million. Global SBS market projected to reach \$4.6 billion by 2027 with a CAGR of 26% from 2020 to 2027 ⁵ (doesn't include potential contribution from crofelemer's novel mechanism of action)
IBS - diarrhea predominant (IBS-D)	3	~15% of adult population Most IBS products have estimated revenue potential >\$1.0 billion ⁶
Symptomatic relief and treatment of diarrhea from cholera and other pathogens	0	*Potential opportunity for Priority Review Voucher (PRV) PRVs are transferable, and in past transactions by other companies have sold for values ranging from \$67 million to \$350 million ⁷

¹ Research and Markets 2017 report: "Global Gastrointestinal agents Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025"

² American Cancer Society. Cancer Facts & Figures 2024. Atlanta: American Cancer Society; 2024

³ <https://www.cdc.gov/cancer/preventinfections/providers.htm#print>

⁴ <https://www.ihealthcareanalyst.com/global-chemotherapy-induced-nausea-vomiting-drugs-market/>


⁵ <https://www.mynewsdesk.com/us/medical-technology-news/pressreleases/short-bowel-syndrome-market-global-industry-analysis-size-share-trends-revenue-forecast-2020-to-2027-3069433>

⁶ <http://247wallst.com/healthcare-business/2015/04/27/key-analyst-sees-nearly-30-upside-in-ironwood> & <https://www.benzinga.com/analyst-ratings/analyst-color/17/03/9224181/analyst-synergy-pharma-could-achieve-sustainable-profit>

⁷ <https://www.raps.org/regulatory-focus/news-articles/2017/12/regulatory-explainer-everything-you-need-to-know-about-fdas-priority-review-vouchers>

How Crofelemer Works

- **Crofelemer is a non-opioid that works differently from other treatments for GI dysfunction**



With crofelemer, it's about waterflow

Crofelemer normalizes waterflow in the GI tract
Less water flowing into your GI tract = less watery diarrhea = greater nutrient absorption opportunity



Crofelemer acts locally in the GI tract



Opioid medicines (i.e., Imodium, loperamide) work by slowing down your GI tract, i.e., opioid constipation risk



Crofelemer is a non-opioid, non-antibiotic, non-addictive drug approved in the US for a chronic use

Our crofelemer clinical development programs

July 23, 2024: Jaguar Reported Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer

- A growing and urgent unmet medical need exists for novel non-opioid chronic agents to treat CTD.
- Unprecedented trial included patients with 10 different tumor types and 24 different targeted agents, with and without multiple standard cytotoxic chemotherapies.
- Study did not meet prespecified analysis of primary endpoint for all tumor types.
- Clinically meaningful signals breast and lung cancers are two of the three most common cancers, with patients often remaining on targeted therapy over prolonged periods.
- **Phase 3 data with significant results in prespecified subgroup of adult patients with breast cancer**
 - Patients with CTD 40% more likely to discontinue chemotherapy or targeted therapy than those without CTD¹
 - The cost of care of CTD patients is estimated to be 2.9 times higher than for patients who are not experiencing CTD²
- Company expects to engage with FDA after full review of data, expected Q3 2025



¹ Pablo C. Okhuysen, M.D. *Impact of Cancer-Related Diarrhea on Changes in Cancer Therapy Patterns: Real World Evidence*

² Eric Roeland, M.D., FAAHPM. *Healthcare Utilization and Costs Associated with Cancer-Related Diarrhea*

Importance of the Patient Voice in Managing Cancer Care Effectively

Paradigm shifting treatment with crofelemer

- Strength of that voice as patients continue targeted therapies for months and years rising, important, and playing a role in what type of cancer treatment fits with the goals and the life of the patient (QoL)
- Patient dignity and comfort paramount
- Cancer patients = everyday people—parents, children, at school, in the workforce





Napo Pharmaceuticals' *Make Cancer Less Shitty* Patient Engagement Program



A NEGLECTED PROBLEM

People with cancer experience numerous challenges – including **treatment-related side effects** – that can impact their quality of life (QoL). Supportive care is critical to addressing these challenges.

In a study of patient-reported chemotherapy side effects,  **6 in 10** participants reported having at least one debilitating side effect.¹

 **81%** of cancer survivors reported they had unmet supportive care needs and reported dissatisfaction with current supportive care services.²

In a survey of oncology community stakeholders (researchers, nurses, medical oncologists, administrators, surgical and radiation oncologists, patient advocates, and nonphysician providers), patient QoL was ranked the most important metric over survival, access to care, and cost.³

There remains an **urgent need** to enhance supportive care as part of overall cancer care to best protect the dignity and QoL of those living with cancer.

REFERENCES
1. Pearce A, Hahn M, Viney R, et al. Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study. *PLoS ONE*. 2017;12(10):e0184200.
2. Moore TM, King AJ, Escoria M, Sharp D, Pineda R, Hurley A, et al. Supportive care for men with prostate cancer: why are the trials not working? A systematic review and recommendations for future trials. *Cancer Med*. 2015;4(8):1240-1251.
3. Khan C, Snyder RA, Horn DM, et al. Defining Priorities in Value-Based Cancer Care: Insights From the Alliance for Clinical Trials in Oncology National Cooperative Group Survey. *JCO Oncol Pract*. 2023;19(10):932-938.

October 2024 Commercial Launch of Gelclair—Jaguar’s 3rd Commercialized Prescription Product

- **Oral mucositis is defined as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force**
 - Gelclair is an FDA-approved mucoprotective gel that coats the surface of the mouth to provide long-lasting relief
- **Who suffers from oral mucositis?**
 - 90% incidence in head and neck radiation¹ and bone marrow transplant
 - 30-75% of all patients receiving chemotherapy
- **Oral mucositis is a dose-limiting side effect of cancer treatment**
 - 19% of patients with head and neck cancer who develop oral mucositis may end up being hospitalized,¹ which can involve interruption of cancer treatment

- ✓ **NO** alcohol or heavy metals
- ✓ **NO** stinging or irritation
- ✓ **NO** numbing agents
- ✓ **NO** known drug interactions



¹ Pulito C, Cristaudo A, Porta C, Zapperi S, Blandino G, Morrone A, Strano S. *Oral mucositis: the hidden side of cancer therapy.* J Exp Clin Cancer Res. 2020 Oct 7;39(1):210. doi: 10.1186/s13046-020-01715-7. PMID: 33028357; PMCID: PMC7542970.

Ongoing Gelclair Campaign



FOR PATIENTS ON CANCER TREATMENT

A SOOTHING SURGE OF RELIEF

FROM ORAL MUCOSITIS PAIN

BE READY WITH GELCLAIR

PATIENTS TREATED WITH THIS PRESCRIPTION NON-PHARMACOLOGIC GEL EXPERIENCED⁵:



SOOTHING RELIEF
for mouth lesions



LASTING REDUCTION
in pain—providing relief up
to 7 hours after each dose



MEANINGFUL IMPROVEMENT
in ability to swallow, eat, and drink



US Oral Mucositis Market Size and Opportunity

- **Oral mucositis often leads to dose reductions or interruptions in cancer therapy**, which can adversely affect overall treatment outcomes.
- Hospitalizations for pain management, nutritional support, and treatment modifications can lead to additional healthcare costs ranging from **\$17,000 to \$42,000 per patient over the course of treatment**.
 - Significant downstream costs
- The global market for oral mucositis treatments is projected to reach approximately **\$2.4 billion by 2027, with North America being the largest market**
- Net revenue for Mytesi in 2023 was \$9.6 million. To match Mytesi 2023 sales, we would need about 3,500 Gelclair patients to be on the product for 30 days each in 2024. This represents about **3.8% of the addressable US market**.



Canalevia®-CA1 (Crofelemer): A New Standard of Care For Treatment of Chemotherapy-induced Diarrhea (CID) in Dogs Launched April 2022

Canalevia-CA1 received conditional approval in December 2021—the first and only product indicated for CID in dogs to receive any type of approval from FDA

Approximately 1 in 4 dogs will, at some stage in their life, develop neoplasia. Almost half of dogs over the age of 10 will develop cancer. ~6 million new cancer diagnoses are made in dogs each year in the U.S.

Pet owners' willingness to pay for life saving treatments and procedures increases with patient comfort.


For the most part, dogs receive human chemotherapeutic agents during treatment and suffer the same side effects as humans, which means ~40% of treated dogs may have their chemotherapy reduced, changed, or discontinued due to diarrhea—which can compromise the full benefit of the chemotherapy agent.

Similar dynamics to human specialty market, but with greater correlation between gross and net revenue with pet owner paying out of pocket.

Conditional approval in dogs is similar to orphan drug designation in humans.



Jaguar Health's Strategic Focus on Rare Diseases



Rare diseases, when taken together, are not that rare at all

- **30 million Americans¹**, or 10 percent of the population, have one of the approximately **7,000 known rare diseases²**
- An estimated **30 to 40 million people in the EU³** and **400 million worldwide⁴** have a rare disease
- Definition of a rare or orphan disease by region:
 - **US:** When a disease affects **<200,000** people⁵
 - **EU:** When a disease affects **<1 in 2,000** people⁶
 - **EU: “Ultra-rare disease”:** When a disease affects **no more than 1 in 50,000** people⁷
- Reimbursement coverage is often available due the rare disease’s high morbidity and mortality rates, and as a result of support from patient activist groups

¹ & ² Source: <https://phrma.org/Scientific-Innovation/Progress-in-Fighting-Rare-Diseases>

³ Source: Harari S. Why We Should Care About Ultra-Rare Disease. Eur Respir Rev. 2016 Jun;25(140):101-3. doi: 10.1183/16000617.0017-2016

⁴ Source: <https://rarediseases.org/rare-disease-day-2022-advancing-the-conversation-around-health-equity/>


⁵ Source: <https://www.fda.gov/patients/rare-diseases-fda#>

⁶ Source: <https://www.eurordis.org/information-support/what-is-a-rare-disease/>

⁷ Source: European Commission Regulation (EU) No.536/2014 of the European Parliament and of the Council of April 16, 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. 2014. Available from: <http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32014R0536&qid=1421232837997&from=EN>

Short Bowel Syndrome – Loss of Bowel with Quality-of-Life Changes

- **SBS:** Catastrophic loss of bowel often due to surgical resection of diseased or necrotic bowel (normal 15-25 feet to 5 or less feet) in adults/children (also may be congenital in children).
- **SBS with Intestinal Failure (SBS-IF):** A condition in which your body is unable to absorb enough nutrients from the foods you eat because you do not have enough small intestine. Patients suffer from malnutrition, dehydration, imbalances of fluids and salts, excessive intestinal fluid output, and risk of organ failure.
 - Life-long parenteral nutrition (PN) may be required
 - No “standard of care” drug intervention



Parenteral nutrition backpack for patients with intestinal failure

A Global Opportunity

- SBS Patient Population:
 - ~10,000 to 20,000 in US
 - ~10,000 to 20,000 in Europe
- Despite limited treatment options, the global SBS market exceeded \$568 million in 2019 and is expected to reach **\$4.6 billion by 2027¹**
 - Gattex (teduglutide; growth hormone):
 - Estimated share of US market: ~1-2%³
 - Annual cost in US: ~\$485,400⁴
 - Multiple biosimilars in development by other companies
 - **“Gattex can make abnormal cells that are already in your body grow faster. There is an increased risk that abnormal cells could become cancer.”**
 - Non-hospitalized parenteral nutrition in the US is approximately \$150,000 per year⁵
 - Frequent hospitalizations for infections



¹ <https://www.mynewsdesk.com/us/medical-technology-news/pressreleases/short-bowel-syndrome-market-global-industry-analysis-size-share-trends-revenue-forecast-2020-to-2027-3069433>

² Jaguar estimate based on projected Gattex 2020 revenue of 554.9M USD (based on Takeda financial reports) divided by annual per-patient expenditure for Gattex of \$376.2K in 2016 (figure sourced from <https://www.ahip.org/documents/HighPriceDrugsReport.pdf>)


³ Jaguar estimate based on an estimated US SBS population of 10,000-20,000 people

(www.crohnscolitisfoundation.org/sites/default/files/legacy/assets/pdfs/short-bowel-disease-crohns.pdf)

⁴ 10 priciest drugs in America (<https://www.benefitspro.com/2020/08/24/10-priciest-drugs-in-america/?slreturn=20221021163553>)

⁵ <https://nutritionequity.org/wp-content/uploads/2018/05/mnea-factsheet-sbs.pdf>

Proposed Treatment Pathway: Crofelemer May Reduce Need for Parenteral Nutrition in SBS-IF Patients



Reduction of parenteral nutrition would lead to improvement of patients' quality of life

Microvillus Inclusion Disease (MVID): An Ultra Rare CDD

MVID is an ultra rare congenital diarrheal disorder (CDD) that affects newborns and children and leads to significant morbidity and mortality from **severe secretory diarrhea, intestinal failure**

Key Milestones:

- **Investigational New Drug (IND) application for crofelemer for MVID activated by FDA in August 2023**
- Single digit number of patients treated to receive approval?



* Adverse events could negatively affect the timeliness of submitting the Investigational New Drug (IND) application. There is a probability that the FDA may not approve Company's IND application.

NP-300 Drug Candidate for the Symptomatic Relief of Diarrhea from Cholera and Other Pathogens

Cholera is designated as a rare disease in the United States, where nearly all reported cases are acquired during international travel

Our NP-300 Drug Candidate:

- Second-generation anti-secretory drug
- Same source plant as crofelemer
- Clinical proof-of-concept for the CFTR ion channel MOA of NP-300 demonstrated by crofelemer for the reduction of diarrhea-associated dehydration in cholera patients: International Centre for Diarrhoeal Disease Research (icddr,b) in Bangladesh
- IND activated
- Plan to pursue Priority Review Voucher (PRV) (in past transactions by other companies PRVs have sold for values ranging from \$67M - \$350M)



Jaguar and Filament Health, with Funding from One Small Planet, Form Joint Venture *Magdalena Biosciences* to Develop Botanical Pharmaceutical Drug Candidates for Mental Health Illnesses

Magdalena currently valued at US\$5.0 million based on initial funding of US\$1.0 million from One Small Planet

- Magdalena Biosciences leverages Jaguar's proprietary 2300 medicinal plant library
- Jaguar currently owns ~40% of Magdalena
- **Goal of Collaboration:** To extend the botanical drug development capabilities of Jaguar to:
 - Develop pharmaceutical-grade, standardized drug candidates for mental health disorders **including attention-deficit/hyperactivity disorder (ADHD) in adults**
 - **Partner with a potential future licensee** to develop and commercialize these novel plant-based drugs



Three IND ready candidates (ADHD, schizophrenia, anxiety). Non dilutive financing

Magdalena Biosciences

Program to support the discovery and development of **novel psychoactive medicines derived from plants** for mental health and CNS disorders

- Leverage Company's proprietary library of ~2,300 plants and ~3,500 plant extracts with ethnomedicinal investigation
- Seeking next generation first-in-class agents, novel mechanisms of action, disease modifying agents

Eight key agents being pursued by psychedelic-focused companies:

- LSD and derivatives
- Psilocybin and derivatives (mushrooms in the genus *Psilocybe*)
- Iboga and derivatives
- Toad sections from *Bufo Alvarius* 5-MeO-DMT
- MDMA (referred to as ecstasy or Molly)
- Ketamine
- Mescaline and derivatives (peyote is most well-known source but not only source)
- DMT and derivatives (most well-known source is the *Banisteriopsis* and *Psychotria viridis* mixture known as Ayahuasca)




Picralima nitida plant, the source of the active ingredient alstonine



Peyote (*Lophophora williamsii*), a source of mescaline

Net Revenue: Q3 2024 net revenue increased approximately 14% versus net Q2 2024 revenue



Expected Upcoming Catalysts – Financial, Clinical & Commercial

- **Ongoing:** Commercial launch (began Oct 2024) of FDA-approved Gelclair product for oral mucositis
- **Ongoing:** Poster presentations at Dec 2024 San Antonio Breast Cancer Symposium.
- **Dec 2024/Jan. 2025:** Initiation of crofelemer IIT in Abu Dhabi in pediatric patients with SBS-IF or MVID
- **Dec 2024:** Initiation of crofelemer IIT at Cleveland Clinic in adult SBS-IF patients
- **Dec 2024:** Initiation by Napo Pharmaceuticals of global Phase 2 study of crofelemer for MVID
- **Jan 2025:** Initiation by Napo Therapeutics of global Phase 2 study of crofelemer in adult SBS-IF patients
- **Q1 2025:** Initiation of two additional crofelemer IITs for SBS-IF and MVID
- **Q2 2025:** Initial proof-of-concept (POC) data available for crofelemer for SBS-IF and MVID in support of potential early patient access in specific EU countries
- **Q2 2025:** Briefing package submitted to FDA on OnTarget results in breast cancer patients for CTD
- **Q2 2025:** Business development deal for development and commercialization of company's NP300 prescription drug candidate for general in dogs
- **Q3 2025:** Meeting with FDA to obtain clarity regarding possible pathways to make crofelemer available as efficiently as possible to breast cancer patients for CTD
- **2025:** Jaguar mental health-focused joint venture Magdalena Biosciences to initiate clinical development for botanical drug candidate
- **1H 2026:** End of Phase 2 trials of crofelemer in SBS-IF and MVID



Jaguar/Napo Pharmaceuticals Executive Management Team

Name / Title	Experience
Lisa Conte Founder & CEO	<ul style="list-style-type: none"> • 30+ years of industry experience • Obtained first anti-secretory human product FDA approval • Board of Directors of Healing Forest Conservancy • Raised over \$400 mm
Carol Lizak, MBA Chief Financial Officer	<ul style="list-style-type: none"> • 20 years corporate controllership and financial planning and analysis experience under U.S. GAAP & IFRS • 10+ years with public companies including foreign subs (5 years in biopharma)
Steven King, PhD Chief Sustainable Supply, Ethnobotanical Research & IP Officer	<ul style="list-style-type: none"> • Served as head of sustainable supply, ethnobotanical research & IP: 1989-2020 • Board of Directors of Healing Forest Conservancy
Pravin Chaturvedi, PhD Chief Scientific Officer Chair of Scientific Advisory Board	<ul style="list-style-type: none"> • 25+ years drug development experience • Co-Founded Scion, IndUS and Oceanyx Pharmaceuticals • Successfully developed Mytesi® (first pivotal adaptive design) and 7 pharmaceutical products
Karen J. Brunke, PhD Executive VP, Corporate & Business Development	<ul style="list-style-type: none"> • 30+ years experience in research, operations and BD in pharma/biotech • Primary responsibility in deals with MedImmune, Astellas; closed GSK deal • Successfully developed GMOs at Sandoz while Research Director
Darlene Horton, M.D. Chief Medical Officer	<ul style="list-style-type: none"> • Biopharmaceutical veteran and leading clinical development expert • 25 years experience in development of investigational and commercialized biopharmaceutical and drug-device combination products; experienced in design of SBS clinical programs
David Sesin, PhD Chief Manufacturing Officer	<ul style="list-style-type: none"> • Pharmaceutical scientist with experience from drug discovery through manufacturing • Developed crofelemer manufacturing process
Jonathan Wolin, JD, MBA Chief of Staff, Chief Compliance Officer & General Counsel	<ul style="list-style-type: none"> • Extensive experience providing legal advice and guidance to public and private companies in the healthcare and biotechnology industries
Ian H. Wendt, MBA Chief Commercial Officer	<ul style="list-style-type: none"> • Has held commercial leadership roles across sales, marketing and operations at some of the largest brands in the pharmaceutical industry over past 25 years
Allison A. Shrier, M.D. Napo Pharmaceuticals VP, Clinical Research & Medical Affairs	<ul style="list-style-type: none"> • Physician-scientist-entrepreneur with expertise in oncology & metabolism • Expertise in end-to-end drug discovery & development including population identification, target product profiles development, hit design, selection & optimization, preclinical & clinical study planning

Investment Highlights

Mytesi (Crofelemer): FDA-Approved Human Drug

- Only FDA-approved diarrhea treatment that's been studied specifically in adults with HIV / AIDS
- Supply chain in place

Planned Crofelemer Expansion

- **Progression from supportive care to impact on outcome/cost of care to treatment modifying**
- Napo's CTD - Phase 3 OnTarget study: Company to complete analysis of full data for first and second 12-week periods of trial in support of FDA discussion
- SBS with intestinal failure - treatment modifying
- 3 IITs (functional diarrhea, IBS, IBD)

Strategic Focus on Rare Diseases

- SBS with intestinal failure
- Initial CDD target indication: microvillus inclusion disease (MVID)
- Other rare diseases, real world PRO

Canalevia-CA1 for chemotherapy-induced diarrhea (CID) in dogs

- Canalevia-CA1 FDA conditionally approved December 2021
- Estimated 6 million new cancer diagnoses in dogs each year in US; 25-40% experience diarrhea
- Management of CID in dogs is a comfort issue for dogs and may also help dogs better tolerate chemo and improve the home/living environment for owners

Strategic Partnerships

- Unencumbered global commercial rights to Mytesi/crofelemer pipeline
- License deals completed in Europe, Canada, Middle East; ongoing discussions for Asia, LATAM
- Magdalena Biosciences leveraging proprietary 2,300-plant ethnobotanical database

Strong Management Team

- Key management has been with the team for >20 years
- Chairman of board and key investors have invested for >30 years

Proprietary Position

- ~192 patents (majority do not expire until 2027 - 2031) and ~42 patents pending
- Sustainable supply of commercial scale of raw material sourcing
- Botanical guidance protection – no practical generic pathway





Jaguar Health, Inc. (NASDAQ: JAGX)

Contact:

hello@jaguar.health

